spec sheet6 rows
FK-960 was Fujisawa Pharmaceutical's (Japan) 1990s answer to a completely different question than most nootropics of its era: instead of chasing acetylcholine or glutamate receptors, it tried to boost memory by stimulating somatostatin release and, downstream, glial production of GDNF (glial cell line-derived neurotrophic factor). Preclinical work showed it ameliorated memory deficits in rodent models and enhanced hippocampal signaling relevant to long-term potentiation. It moved through animal and early-stage research toward a possible Alzheimer's disease application, but somatostatin-boosting drugs never carved out a clinical niche in dementia care, and FK-960 stalled well short of approval, remembered now mostly in pharmacology reviews as a case study in an alternate route to memory enhancement.
- ameliorated memory deficits in rodent behavioral models
- increased somatostatin release relevant to hippocampal function
- boosted GDNF production in cultured astrocytes, a neurotrophic mechanism distinct from cholinergic drugs
- FK-960 doesn't touch a classic neurotransmitter receptor at all; its headline effect was boosting somatostatin and GDNF release from glial cells, a mechanism almost nobody else in 1990s nootropic research was chasing.
Mechanism
FK-960 (a piperazinyl-benzamide derivative) stimulates somatostatin release in the brain and increases glial production of GDNF, an indirect route to enhancing transmission and memory circuits rather than direct receptor agonism.
Safetyrisks and cautions, not medical advice
Fujisawa carried FK-960 into Phase 2 for Alzheimer's disease and for cognitive disorders, and both programmes were shut down, the American one in 2003 and the European one in July 2004. No results from either were ever published, so people were dosed and the record of what happened to them is not public. Everything readable today is rodent and cell work, which means the human tolerability profile, the dose ceiling and the interaction profile are all genuinely unknown rather than merely reassuring.
History
Developed by Fujisawa Pharmaceutical (Japan) in the 1990s; studied through preclinical memory models and reviewed as an investigational Alzheimer's approach in the early 2000s before fading from active development.
Subjective profileweighing the evidence above
An interesting somatostatin/GDNF-based side door into memory pharmacology that never got a real human trial to test the idea properly.
Resources
This entry is here for reference.
Research
- 1996first citedFK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits…
- 2004most recentThe potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's di…
- 1.FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action.
- 2.Increase by FK960, a novel cognitive enhancer, in glial cell line-derived neurotrophic factor production in cultured rat astrocytes.
- 3.The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease
3 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is FK-960 the same as classic nootropics like piracetam?
No. Its mechanism is unrelated to the racetam family; it works through somatostatin release and glial GDNF production rather than glutamate or cholinergic receptors.
Did FK-960 ever reach human trials?
Public documentation is limited mostly to preclinical animal studies and pharmacology reviews; there is no well-documented completed human efficacy trial.
Limitations of the evidence
- limited to preclinical/early research data; no established human safety profile
- mechanism (somatostatin/GDNF modulation) carries theoretical off-target effects that were never fully characterized in humans